B. Johnson

发表

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

K. Götze, P. Greenberg, A. Verma, 2015, The Lancet. Haematology.

A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum

R. Borchardt, C. Porter, W. Charman, 2003, Journal of Pharmacology and Experimental Therapeutics.

Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months

J. Barrett, P. Adamson, C. Coté, 2009, European Journal of Clinical Pharmacology.

A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.

J. Friedberg, O. Hyrien, L. Constine, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease

Sung Gyun Kim, J. Lepore, S. Zeig, 2018, Clinical kidney journal.

Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.

C. Porter, W. Charman, B. Johnson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients

F. Chung, J. Pergolizzi, S. Singla, 2010, Anesthesiology.

Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863

B. Johnson, S. Caltabiano, Brendt Stier, 2014, Clinical pharmacology in drug development.

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

M. Sahay, M. Westerman, S. Roger, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients

S. Murray, B. Johnson, L. Adams, 2014, Clinical pharmacology in drug development.

CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS

Peijin Zhang, K. Brouwer, J. Schuetz, 2006, Drug Metabolism and Disposition.

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

S. Swan, S. Murray, T. Marbury, 2012, Investigational New Drugs.

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

J. Lepore, B. Johnson, A. Cobitz, 2018, Clinical kidney journal.

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

P. Lebowitz, B. Johnson, L. Adams, 2009, Supportive Care in Cancer.

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure

G. Serbest, B. Johnson, A. Cobitz, 2019, Clinical kidney journal.

Genetically Engineered Extracellular Vesicles Harboring Transmembrane Scaffolds Exhibit Differences in Their Size, Expression Levels of Specific Surface Markers and Cell-Uptake

G. Marriott, Annie Brown, B. Johnson, 2022, Pharmaceutics.

Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.

A. Rastogi, J. Lepore, S. Zeig, 2016, Journal of the American Society of Nephrology : JASN.

Investigation of the Thermal Properties of Rice Husk Ash in Cement

B. Johnson, Abbey L Teliska, D. R. Stomski, 2017 .

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

E. Heath, J. Botbyl, W. Schelman, 2012, Cancer Chemotherapy and Pharmacology.

Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia

D. Ouellet, P. Mudd, B. Johnson, 2013, Cancer Chemotherapy and Pharmacology.

An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine

Christopher J. H. Porter, C. Porter, W. Charman, 2002, AAPS PharmSci.

Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study

R. Ramlau, H. Safran, B. Karaszewska, 2014, Cancer medicine.

Effect of Casopitant, a Novel NK‐1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady‐State Warfarin

S. Murray, S. Morris, B. Johnson, 2010, Journal of clinical pharmacology.

MODULATION OF HEPATIC CANALICULAR OR BASOLATERAL TRANSPORT PROTEINS ALTERS HEPATOBILIARY DISPOSITION OF A MODEL ORGANIC ANION IN THE ISOLATED PERFUSED RAT LIVER

Peijin Zhang, K. Brouwer, B. Johnson, 2005, Drug Metabolism and Disposition.

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

P. Lebowitz, B. Johnson, L. Adams, 2009, Supportive Care in Cancer.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Disposition and Metabolism of Radiolabeled Casopitant in Humans

B. Johnson, A. Roberts, M. Pellegatti, 2009, Drug Metabolism and Disposition.

A novel method for the determination of biliary clearance in humans

W. Heizer, K. Brouwer, B. Johnson, 2004, The AAPS Journal.